Tango Therapeutics reports 82% tumour response rate for combination therapy in MTAP-deleted pancreatic cancer
Early-phase data presented at ESMO 2026 show a high response rate for vopimetostat plus a RAS inhibitor in patients whose pancreatic tumours carry a specific genomic deletion.
Tango Therapeutics has reported that 82% of patients with MTAP-deleted advanced pancreatic cancer showed tumour responses in a clinical trial of vopimetostat — a MAT2A inhibitor — combined with daraxonrasib (RAS-ON inhibitor, also known as RASonque), developed by Revolution Medicines. The results were disclosed at ESMO 2026.
MTAP deletion is a relatively common genomic event in pancreatic ductal adenocarcinoma and several other tumour types. It creates a metabolic vulnerability that MAT2A inhibitors are designed to exploit by depleting methionine, an amino acid on which MTAP-deleted tumours disproportionately depend. The combination with RAS pathway inhibition represents a synthetic-lethality and co-targeting strategy designed to address the limited therapeutic options currently available for pancreatic cancer with KRAS mutations.
These are early-phase results and the response rate — while striking — was observed in a selected population and a relatively small number of patients; the trial is not phase 3. Published peer-reviewed data have not yet appeared in the literature at the time of publication. Oncologists and researchers working in pancreatic cancer genomics will be watching whether response depth and duration are confirmed in larger cohorts.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers from Tango Therapeutics and Revolution Medicines have shared early trial results for a two-drug combination being tested in people with advanced pancreatic cancer whose tumours carry a specific genetic change called MTAP deletion. In this early trial, eight out of ten patients with this type of tumour saw their cancer shrink. The two drugs work by targeting a weakness that appears in cancer cells when the MTAP gene is missing. These results were presented at a major cancer conference called ESMO 2026, but the trial is still at an early stage, involved a small number of patients, and the drugs are not yet approved for standard use. Larger trials will be needed to understand how long the benefit lasts and who benefits most. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-23STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
-
Stat News · 2026-10-23One family's story of a life-extending medicine for pancreatic cancer